GT201200219A - Derivados de pirazina y uso en el tratamiento de trastornos neurológicos - Google Patents

Derivados de pirazina y uso en el tratamiento de trastornos neurológicos

Info

Publication number
GT201200219A
GT201200219A GT201200219A GT201200219A GT201200219A GT 201200219 A GT201200219 A GT 201200219A GT 201200219 A GT201200219 A GT 201200219A GT 201200219 A GT201200219 A GT 201200219A GT 201200219 A GT201200219 A GT 201200219A
Authority
GT
Guatemala
Prior art keywords
treatment
neurological disorders
pirazine
derivatives
pirazine derivatives
Prior art date
Application number
GT201200219A
Other languages
English (en)
Spanish (es)
Inventor
Tintelnot-Blomley Marina
Veenstra Siem Jacob
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43598456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201200219(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201200219A publication Critical patent/GT201200219A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GT201200219A 2009-12-31 2012-06-28 Derivados de pirazina y uso en el tratamiento de trastornos neurológicos GT201200219A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29172409P 2009-12-31 2009-12-31

Publications (1)

Publication Number Publication Date
GT201200219A true GT201200219A (es) 2013-10-10

Family

ID=43598456

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201200219A GT201200219A (es) 2009-12-31 2012-06-28 Derivados de pirazina y uso en el tratamiento de trastornos neurológicos

Country Status (27)

Country Link
US (2) US20120277244A1 (enExample)
EP (1) EP2519515B1 (enExample)
JP (1) JP5600754B2 (enExample)
KR (1) KR101419157B1 (enExample)
CN (1) CN102712621B (enExample)
AU (1) AU2010338365B2 (enExample)
BR (1) BR112012015916A2 (enExample)
CA (1) CA2785341A1 (enExample)
CL (1) CL2012001762A1 (enExample)
CR (1) CR20120332A (enExample)
CU (1) CU20120099A7 (enExample)
EA (1) EA201200952A1 (enExample)
EC (1) ECSP12012065A (enExample)
ES (1) ES2445536T3 (enExample)
GT (1) GT201200219A (enExample)
HN (1) HN2012001413A (enExample)
IL (1) IL220268A0 (enExample)
MX (1) MX2012007754A (enExample)
NZ (1) NZ600136A (enExample)
PE (1) PE20121640A1 (enExample)
PH (1) PH12012501007A1 (enExample)
PL (1) PL2519515T3 (enExample)
PT (1) PT2519515E (enExample)
SG (1) SG181431A1 (enExample)
TN (1) TN2012000249A1 (enExample)
WO (1) WO2011080176A1 (enExample)
ZA (1) ZA201203614B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2537898T3 (es) 2005-10-25 2015-06-15 Shionogi & Co., Ltd. Derivados de aminotiazolidina y aminotetrahidrotiazepina como inhibidores de BACE 1
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
AU2008245082B8 (en) 2007-04-24 2012-09-13 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
WO2010047372A1 (ja) 2008-10-22 2010-04-29 塩野義製薬株式会社 Bace1阻害活性を有する2-アミノピリミジン-4-オンおよび2-アミノピリジン誘導体
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
RU2012129168A (ru) 2009-12-11 2014-01-20 Сионоги Энд Ко. Лтд. Производные оксазина
AR081587A1 (es) 2010-06-09 2012-10-03 Janssen Pharmaceutica Nv DERIVADOS DE 5,6-DIHIDRO-2H-[1,4]OXAZIN-3-IL-AMINA UTILES COMO INHIBIDORES DE LA b-SECRETASA (BACE)
EA201291366A1 (ru) * 2010-06-09 2013-04-30 Янссен Фармацевтика Нв Производные 5-амино-3,6-дигидро-1h-пиразин-2-она в качестве ингибиторов бета-секретазы (bace)
SG186408A1 (en) * 2010-06-28 2013-01-30 Janssen Pharmaceutica Nv 3-amino-5, 6-dihydro-1h-pyrazin-2-one derivatives useful for the treatment of alzheimer's disease and other forms of dementia
CA2816285A1 (en) 2010-10-29 2012-05-03 Shionogi & Co., Ltd. Naphthyridine derivative
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
ES2648143T3 (es) 2010-12-22 2017-12-28 Janssen Pharmaceutica Nv Derivados de 5,6-dihidro-imidazo[1,2-a]pirazin-8-ilamina útiles como inhibidores de la beta-secretasa (BACE)
US8524897B2 (en) 2011-01-12 2013-09-03 Novartis Ag Crystalline oxazine derivative
KR101569260B1 (ko) 2011-01-13 2015-11-13 노파르티스 아게 신규 헤테로시클릭 유도체 및 신경계 장애의 치료에서의 그의 용도
EA201391033A1 (ru) * 2011-01-13 2014-01-30 Новартис Аг Ингибиторы bace-2 для лечения метаболических расстройств
US9346811B2 (en) 2011-03-01 2016-05-24 Janssen Pharmaceutica Nv 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (BACE)
JP5853035B2 (ja) 2011-03-09 2016-02-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap β−セクレターゼ(BACE)の阻害剤として有用な3,4−ジヒドロ−ピロロ[1,2−a]ピラジン−1−イルアミン誘導体
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
BR112013026341A2 (pt) 2011-04-13 2019-09-24 Merck Sharp & Dohe Corp. composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia
WO2012147763A1 (ja) 2011-04-26 2012-11-01 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するbace1阻害剤
RU2014111055A (ru) 2011-08-22 2015-09-27 Мерк Шарп И Доум Корп. 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение
US8338413B1 (en) 2012-03-07 2012-12-25 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
JP2016501827A (ja) 2012-10-24 2016-01-21 塩野義製薬株式会社 Bace1阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体
CN104870000A (zh) 2012-12-20 2015-08-26 默沙东公司 作为bace抑制剂的c5,c6氧杂环稠合的亚胺基噻嗪二氧化物化合物,组合物及其用途
KR102243134B1 (ko) 2013-06-12 2021-04-22 얀센 파마슈티카 엔.브이. 베타-세크레타제(bace) 저해제로서의 4-아미노-6-페닐-5,6-디하이드로이미다조[1,5-a]피라진 유도체
EP3008067B1 (en) 2013-06-12 2017-03-29 Janssen Pharmaceutica N.V. 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2h)-one derivatives as inhibitors of beta-secretase (bace)
BR112015030597A2 (pt) 2013-06-12 2017-07-25 Janssen Pharmaceutica Nv derivados 4-amino-6-fenil-6,7-di-hidro[1,2,3]triazolo[1,5-a]pirazina como inibidores de beta-secretase (bace)
JP2017538753A (ja) 2014-12-18 2017-12-28 ヤンセン ファーマシューティカ エヌ.ベー. 2,3,4,5−テトラヒドロピリジン−6−アミンおよび3,4−ジヒドロ−2H−ピロール−5−アミンの化合物のβセクレターゼ阻害剤
CN107011134B (zh) * 2017-04-28 2021-02-05 浙江中欣氟材股份有限公司 一种2-氟-5-溴苯乙酮的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6911868A (enExample) 1968-08-31 1970-03-03
AUPQ319899A0 (en) * 1999-10-01 1999-10-28 Fujisawa Pharmaceutical Co., Ltd. Amide compounds
WO2002060492A1 (en) * 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7728025B2 (en) 2003-12-29 2010-06-01 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted benzimidazole derivative
US20050215884A1 (en) * 2004-02-27 2005-09-29 Greicius Michael D Evaluation of Alzheimer's disease using an independent component analysis of an individual's resting-state functional MRI
ES2537898T3 (es) * 2005-10-25 2015-06-15 Shionogi & Co., Ltd. Derivados de aminotiazolidina y aminotetrahidrotiazepina como inhibidores de BACE 1
PT2404919E (pt) * 2005-11-08 2013-10-22 Vertex Pharma Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp
EP2094682A2 (en) * 2006-12-22 2009-09-02 Novartis AG Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
BRPI0906962B8 (pt) 2008-01-18 2021-05-25 Eisai R&D Man Co Ltd composto de aminodiidrotiazina fundido
WO2010047372A1 (ja) 2008-10-22 2010-04-29 塩野義製薬株式会社 Bace1阻害活性を有する2-アミノピリミジン-4-オンおよび2-アミノピリジン誘導体
UY32799A (es) * 2009-07-24 2011-02-28 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
EA201291366A1 (ru) * 2010-06-09 2013-04-30 Янссен Фармацевтика Нв Производные 5-амино-3,6-дигидро-1h-пиразин-2-она в качестве ингибиторов бета-секретазы (bace)
SG186408A1 (en) * 2010-06-28 2013-01-30 Janssen Pharmaceutica Nv 3-amino-5, 6-dihydro-1h-pyrazin-2-one derivatives useful for the treatment of alzheimer's disease and other forms of dementia

Also Published As

Publication number Publication date
KR101419157B1 (ko) 2014-07-11
HN2012001413A (es) 2015-03-23
PH12012501007A1 (en) 2013-01-14
TN2012000249A1 (en) 2013-12-12
CU20120099A7 (es) 2012-07-31
ES2445536T3 (es) 2014-03-03
NZ600136A (en) 2013-09-27
PT2519515E (pt) 2014-02-17
CA2785341A1 (en) 2011-07-07
EP2519515A1 (en) 2012-11-07
CN102712621B (zh) 2015-03-11
JP5600754B2 (ja) 2014-10-01
JP2013516395A (ja) 2013-05-13
IL220268A0 (en) 2012-07-31
PE20121640A1 (es) 2012-12-17
US20120277244A1 (en) 2012-11-01
WO2011080176A1 (en) 2011-07-07
BR112012015916A2 (pt) 2017-04-25
PL2519515T3 (pl) 2014-04-30
EA201200952A1 (ru) 2013-02-28
KR20120102795A (ko) 2012-09-18
MX2012007754A (es) 2012-08-01
CN102712621A (zh) 2012-10-03
AU2010338365A1 (en) 2012-06-07
SG181431A1 (en) 2012-07-30
EP2519515B1 (en) 2013-11-06
CR20120332A (es) 2012-07-12
AU2010338365B2 (en) 2014-01-30
HK1172023A1 (en) 2013-04-12
US20150322038A1 (en) 2015-11-12
ZA201203614B (en) 2013-01-30
ECSP12012065A (es) 2012-08-31
CL2012001762A1 (es) 2012-12-21

Similar Documents

Publication Publication Date Title
ECSP12012065A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
UY32799A (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
GT201300179A (es) Derivados heterociclicos novedosos y su uso en el tratamiento de trastornos neurologicos
ECSP12011692A (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
UY33883A (es) Novedosos derivados heterocíclicos
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
UY33541A (es) N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidas
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
ECSP11011079A (es) Nuevos compuestos de hidroxiareno.
UY35320A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA SUSTITUIDA CON HETEROARILO?.
NI201100223A (es) Derivados de imidazolidina 2 -0ne 1,3 - disustituidos como inhibidores de cyp 17
CO6351738A2 (es) Compuestos organicos
UY33458A (es) Derivados de metoxifenilo heterocíclicamente sustituidos con un grupo oxo, procedimientos para su preparación y uso de los mismos como medicamentos
GT201400031A (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
DOP2015000076A (es) Benzamidas
UY32747A (es) 2-carboxamida-cicloamino-ureas sustituidas
UY32404A (es) 4-aril-butan-1,3-diamidas
UY33176A (es) Derivados de oxazolopirimidina sustituida en 2, 5, 7.
UY32748A (es) 2-carboxamida-cicloamino-ureas
CR11759A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
DOP2006000087A (es) Compuestos heteroaromaticos acilaminobiciclicos y sus usos
UY33180A (es) Derivados de ácido carboxílico heterocíclicos que comprenden un anillo de oxazolopirimidina 2,5-sustituida.